Treatment of acute myeloid leukaemia according to the Hammersmith protocol: preliminary report.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D002648:Child; D003561:Cytarabine / Q000627:therapeutic use*; D003630:Daunorubicin / Q000627:therapeutic use*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D004915:Leukemia, Erythroblastic, Acute / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008131:London; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use*; D012075:Remission, Spontaneous; D013866:Thioguanine / Q000627:therapeutic use*
D003561:Cytarabine; D011239:Prednisolone; D013866:Thioguanine; D003630:Daunorubicin